Search research articles
Contact Us
Filters
Showing results (21-30 of 56) with videos related to
Page
of 6
Sort By:
BMC Cancer
|
September 23, 2023
Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound
Laura Spiers, Michael Gray, Paul Lyon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 4, 2011
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma
John M Kirkwood, Lars Bastholt, Caroline Robert, et al.
Journal of Clinical Pharmacology
|
July 3, 2002
Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2
Mark Middleton, Mark Sarno, Sanjiv S Agarwala, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 5, 2009
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline
Claus Garbe, Ketty Peris, Axel Hauschild, et al.
Cancer Chemotherapy and Pharmacology
|
September 29, 2011
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Suzanne Leijen, Patricia M M B Soetekouw, T R Jeffry Evans, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 4, 2019
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity
Sophie Postel-Vinay, Karin Herbschleb, Christophe Massard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 18, 2012
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012
Claus Garbe, Ketty Peris, Axel Hauschild, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2016
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016
Claus Garbe, Ketty Peris, Axel Hauschild, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2008
Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors
Sarah A Lowndes, Avril Adams, Anthony Timms, et al.
Iscience
|
March 27, 2023
Pseudotime dynamics of T cells in pancreatic ductal adenocarcinoma inform distinct functional states within the regulatory and cytotoxic T cells
Ashwin Jainarayanan, Nithishwer Mouroug-Anand, Edward H Arbe-Barnes, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 56) with videos related to
Sort By:
Page
of 6
BMC Cancer
|
September 23, 2023
Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound
Laura Spiers, Michael Gray, Paul Lyon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 4, 2011
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma
John M Kirkwood, Lars Bastholt, Caroline Robert, et al.
Journal of Clinical Pharmacology
|
July 3, 2002
Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2
Mark Middleton, Mark Sarno, Sanjiv S Agarwala, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 5, 2009
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline
Claus Garbe, Ketty Peris, Axel Hauschild, et al.
Cancer Chemotherapy and Pharmacology
|
September 29, 2011
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Suzanne Leijen, Patricia M M B Soetekouw, T R Jeffry Evans, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 4, 2019
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity
Sophie Postel-Vinay, Karin Herbschleb, Christophe Massard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 18, 2012
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012
Claus Garbe, Ketty Peris, Axel Hauschild, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2016
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016
Claus Garbe, Ketty Peris, Axel Hauschild, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2008
Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors
Sarah A Lowndes, Avril Adams, Anthony Timms, et al.
Iscience
|
March 27, 2023
Pseudotime dynamics of T cells in pancreatic ductal adenocarcinoma inform distinct functional states within the regulatory and cytotoxic T cells
Ashwin Jainarayanan, Nithishwer Mouroug-Anand, Edward H Arbe-Barnes, et al.
Page
of 6